...
首页> 外文期刊>Journal of Microbiology and Antimicrobials >In vitro activity of aminoglycosides, lactam- lactamases inhibitor combinations and tetracyclines against multi-drug resistant Acinetobacter baumannii, isolated from a tertiary care hospital
【24h】

In vitro activity of aminoglycosides, lactam- lactamases inhibitor combinations and tetracyclines against multi-drug resistant Acinetobacter baumannii, isolated from a tertiary care hospital

机译:从一家三级医院分离的氨基糖苷类,内酰胺-内酰胺酶抑制剂组合和四环素类药物对多重耐药的鲍曼不动杆菌的体外活性

获取原文
           

摘要

Acinetobacter baumannii?has emerged as a significant nosocomial pathogen, particularly in intensive care units. Isolates of?A. baumannii?resistant to major groups of antibiotics have been identified. These multi-drug resistant (MDR) organisms are limiting the treatment options. The study was performed to determine the?in vitro?activity of aminoglycosides, β lactam- β lactamase inhibitor combinations and tetracyclines against MDR?A. baumannii, isolated from a tertiary care hospital. The study was carried out from January, 2009 - August, 2009, at the Department of Microbiology, Army Medical College/National University of Sciences and Technology, Rawalpindi, Pakistan looking after an 1100 bedded tertiary care hospital. Routine clinical specimens were received from various wards.?A. baumannii?was identified by using standard microbiological procedures. Antimicrobial susceptibility test (gentamicin, amikacin, tobramycin, ampicillin-sulbactam, piperacillin-tazobactam, cefoperazone-sulbactam, tetracycline, doxycycline, minocycline, tigecycline,) was performed according to CLSI guidelines using Kirby-Bauer disc diffusion technique. Resistance to carbapenems, fluoroquinolones and the beta-lactams were observed in significant proportion of fifty isolates. Among the aminoglycosides, the isolates were more?susceptible to tobramycin than gentamicin and amikacin. Cefoperazone-sulbactam was superior to piperacillin-tazobactam and ampicillin-sulbactam in activity against MDR?A. baumannii. Both tigecycline and minocycline were the active agents against most isolates. Multidrug resistantAcinetobacter?infections are posing an increasing threat to our population. Minocycline, tobramycin and cefoperazone-sulbactam provide?an effective option against infections caused by resistant?A. baumannii.
机译:鲍曼不动杆菌已经作为重要的医院病原体出现,特别是在重症监护病房中。隔离?已经鉴定出对主要抗生素具有耐药性的鲍曼氏菌。这些多药耐药性(MDR)生物限制了治疗选择。进行研究以确定氨基糖苷类,β-内酰胺-β-内酰胺酶抑制剂组合和四环素类药物对MDR?A的体外活性。鲍曼氏菌,从三级医院分离。该研究于2009年1月至2009年8月在巴基斯坦拉瓦尔品第的陆军医学院/国家科学技术大学微生物学系进行,负责照顾一家有1100张病床的三级护理医院。从各个病房收到常规的临床标本。鲍曼氏菌是通过标准的微生物学方法鉴定的。抗菌药敏试验(庆大霉素,丁胺卡那霉素,妥布霉素,氨苄青霉素-舒巴坦,哌拉西林-他唑巴坦,头孢哌酮-舒巴坦,四环素,多西环素,米诺环素,替加环素)使用Kirby-Bauer纸片扩散技术根据CLSI指南进行。在五十个分离株中,对碳青霉烯类,氟喹诺酮类和β-内酰胺类的耐药性很高。在氨基糖苷类中,与庆大霉素和丁胺卡那霉素相比,分离物对妥布霉素的敏感性更高。头孢哌酮舒巴坦在抗MDR?A方面优于哌拉西林-他唑巴坦和氨苄西林-舒巴坦。鲍曼尼替加环素和米诺环素都是针对大多数分离物的活性剂。多药耐药性不动杆菌感染对我们的人口构成越来越大的威胁。米诺环素,妥布霉素和头孢哌酮舒巴坦提供了对抗由耐药菌引起的感染的有效选择。鲍曼尼

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号